FIELD: biotechnology.
SUBSTANCE: invention relates to a method for identification of candidate compounds that reprogram the histone-tagging protein from binding its related histone tag to binding to an unrelated histone tail tag, comprising: (a) calculated obtaining of a structural model of the active site of the transcribing protein in combination with an unrelated target histone tail tag, where the active site is modeled with a site for binding compounds candidate; (b) obtaining of a probe structure selected for non-competitive binding to the histone tail tag at the site to bind candidate compounds so as to form a stable triple reprogramming complex with the histone tail tag target and the active site of the transcribing; and (c) candidate compounds screening to identify those that, together with residues in the active site and the target tag of the histone tail, substantially reproduce one or more functional feature involved in the formation of a stable triple reprogramming complex.
EFFECT: improved method.
16 cl, 12 dwg, 5 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
HUMAN EZH2 INHIBITORS AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2618475C2 |
METHOD FOR NUCLEOSOMES ADDUCTS DETECTION | 2012 |
|
RU2634266C2 |
HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
EPIGENETIC REGULATORY COMPLEX OF GENE EXPRESSION CONTROL | 2007 |
|
RU2462512C2 |
METHOD OF PRODUCING OF PLURIPOTENT STEM CELLS | 2014 |
|
RU2565548C1 |
SALT FORM OF HUMAN HISTONE METHYLTRANSERASE EZH2 INHIBITOR | 2013 |
|
RU2658911C2 |
COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
Authors
Dates
2017-12-04—Published
2013-02-27—Filed